DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to p ...

Scorpius (NYSEMKT:SCPX) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering. The company has also priced these shares at $1 each. That will see it generate gross proceeds of $125 million from this offering. Additionally, underwriters have a 45-day option to acquire another 1.875 million shares of SCPX stock at the offering price. This could provide the company with a ...

Form 8-K Current Report [Item 2.02. Results of Operations and Financial Condition](index=1&type=section&id=Item%202.02.%20Results%20of%20Operations%20and%20Financial%20Condition) Scorpius Holdings, Inc. announced preliminary unaudited Q2 2024 financial results, projecting revenue between **$0.3 million and $0.8 million** and an operating loss of **$8.6 million to $9.1 million**, with larger cGMP manufacturing contracts expected to contribute to revenue starting Q3 2024 Preliminary Unaudited Financial Estimates for Q2 2024 | Financial Metric | Estimated Range (in millions) | | :--- | :--- | | Revenue | $0.3 - $0.8 | | Operating Loss | $8.6 - $9.1 | | Net Loss Before Income Taxes (from continuing operations) | $9.2 - $9.7 | - As of June 30, 2024, the company's cash, cash equivalents, and short-term investments were approximately **$1.5 million**[3](index=3&type=chunk) - Revenue for the first six months of 2024 was primarily from process development work, with anticipated revenue generation from microbial cGMP manufacturing, which began in July 2024, and mammalian cGMP manufacturing, expected to start in Q3 2024, with these manufacturing contracts projected to be larger than current process development contracts[3](index=3&type=chunk) - The provided financial estimates are preliminary, based on currently available information, and are subject to adjustments upon completion of the company's financial closing procedures, and have not been audited or reviewed by the company's independent registered public accounting firm[4](index=4&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section details the exhibits filed as part of the Form 8-K report - Exhibit 104, the Cover Page Interactive Data File, was filed with this report[2](index=2&type=chunk)[5](index=5&type=chunk)

Scorpius Holdings, Inc. Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purposebuilt U.S. facilities, Scorpius is dedicated to transparen ...

Scorpius has previously initiated cGMP activities in its microbial facilities, and the commencement of mammalian cGMP campaigns marks a significant development as it opens additional revenue streams for the Company's CDMO operations. Scorpius boasts a dedicated mammalian cell culture facility with cGMPcompliant controlled cleanrooms illustrating Scorpius' commitment to providing tailored and adaptable manufacturing solutions. Scorpius Holdings Inc. is an integrated contract development and manufacturing org ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic and cell therapy programs [2] - The company provides a wide range of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas [2] Reverse Stock Split Announcement - At the Annual Meeting held on July 15, 2024, stockholders approved a reverse stock split of the company's Common Stock at a ratio of 1-for-200 [1] - The reverse stock split aims to increase the selling price of the Common Stock to regain compliance with NYSE American requirements [6] - The reverse stock split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, with trading on a post-split basis commencing on July 18, 2024 [3][6] Compliance and Future Outlook - The company is seeking to regain compliance with NYSE American requirements through the reverse stock split, although there is no assurance that this will be successful [6] - The ownership percentage of each stockholder will remain unchanged, except for fractional shares [1]

Core Points - Scorpius Holdings, Inc. approved a 1-for-200 reverse stock split to increase the selling price of its common stock and regain compliance with NYSE American requirements [2][3] - The reverse stock split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, with trading on a post-split basis commencing on July 18, 2024 [7] - The ownership percentage of each stockholder will remain unchanged, except for fractional shares [2] Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic and cell therapy programs [8] - The company provides a wide range of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas [8] - Scorpius emphasizes transparent collaboration and high-quality biologics biomanufacturing [8]

Financial Results - Scorpius Holdings, Inc. reported financial results for the quarter ended March 31, 2024, with a press release issued on May 29, 2024[4]. - The company has not disclosed specific financial metrics or performance indicators in the provided documents[5]. - The press release attached as Exhibit 99.1 contains detailed financial information, which is not included in the current report[5]. Stockholder Information - The 2024 Annual Meeting of Stockholders is scheduled for August 2, 2024, with a record date of June 13, 2024[7]. - Stockholder proposals for the 2024 Annual Meeting must be received by June 8, 2024, to be considered for inclusion in the proxy materials[8]. - Timely notice for director nominations or other proposals must also be delivered by June 8, 2024[9]. Company Classification and Compliance - The company is not classified as an emerging growth company under the Securities Act[3]. - The filing does not include any new or revised financial accounting standards compliance[3]. Product and Market Insights - The report does not provide any insights into new products, technologies, or market expansion strategies[5]. Company Listing - The company is listed on NYSE American LLC under the trading symbol SCPX[2].